FDA Ends Semaglutide Shortage: What Compounding Patients Must Do Now

The legal ground just shifted under roughly 500,000 Americans taking compounded semaglutide. On February 19, 2025, the FDA removed injectable semaglutide from its drug shortage list—the regulatory loophole that allowed compounding pharmacies to produce the weight-loss medication legally for the past two years. Patients now face a 60-day grace period before compounders must stop producing these versions entirely, with enforcement letters already arriving at major telehealth operators including Hims & Hers, Ro, and Henry Meds.

This isn't a surprise crackdown. It's the predictable endpoint of a regulatory exemption that was always temporary by design. What catches patients off guard is the speed: 60 days to transition from $199-per-month compounded injections to $968.52-per-month Wegovy, assuming insurance won't cover it. For the 71.3% of compounded semaglutide users without prior authorization for brand-name GLP-1s, according to a January 2026 Truepill survey, the math doesn't work.

The Regulatory Timeline That Got Us Here

Compounded semaglutide existed in regulatory gray space since late 2022, when Novo Nordisk couldn't manufacture enough Wegovy and Ozempic to meet demand. The FDA's drug shortage designation triggered Section 503A of the Federal Food, Drug, and Cosmetic Act—allowing licensed compounding pharmacies to produce copies of the medication using the same active pharmaceutical ingredient, semaglutide base or semaglutide sodium.

Novo Nordisk resolved its manufacturing constraints by mid-2024. Tirzepatide came off the shortage list in October 2024. Semaglutide followed on February 19, 2025. The statute is unambiguous: once a drug exits shortage status, compounding must cease within 60 days unless the pharmacy can demonstrate the compounded version is "significantly different" from the FDA-approved product—a nearly impossible standard when you're using identical active ingredients.

By April 20, 2025, production stops. Existing inventory can be dispensed until expiration, typically 30-90 days depending on formulation and storage.

What Telehealth Companies Are Actually Doing

The response varies by operator size and legal risk tolerance. Hims & Hers announced February 21 it would stop prescribing compounded semaglutide effective immediately, pivoting customers toward compounded tirzepatide or branded options. The company faces a lawsuit from Novo Nordisk over its brief experiment with oral compounded semaglutide tablets in late 2024—a product the FDA explicitly warned against in September 2025 guidance.

Ro sent notifications to existing patients offering transitions to Wegovy with "insurance navigation support" but no price guarantees. Their compounded semaglutide program, launched in 2023, served approximately 85,000 patients at its peak in mid-2024, based on company earnings disclosures.

Smaller operations are going quiet. Henry Meds stopped accepting new semaglutide patients March 1 but continues fulfilling existing prescriptions during the wind-down period. A network of boutique medical spas and wellness clinics in Florida, Texas, and Arizona—states with particularly permissive compounding regulations—are advertising "limited remaining inventory" and steering customers toward membership programs that stockpile 90-day supplies before the cutoff.

That last approach carries legal exposure. The FDA's February 28 guidance memo explicitly prohibits "excessive inventory accumulation for the purpose of circumventing the end of shortage-based compounding." Pharmacies found warehousing bulk semaglutide face referral to the DOJ for potential prosecution under misbranding statutes.

Your Actual Options, Ranked by Cost

Branded semaglutide with insurance coverage: $25-$150 per month if your plan includes Wegovy or Ozempic on formulary with prior authorization. Novo Nordisk's savings card covers up to $650 per month for commercially insured patients with BMI ≥27 and at least one weight-related comorbidity. Medicare and Medicaid enrollees don't qualify for manufacturer coupons under federal anti-kickback rules. Success rate for prior authorization: 43.7% on first submission, per a 2024 Harvard Pilgrim analysis.

Branded semaglutide cash price: $968.52 per month for Wegovy at CVS (2.4mg maintenance dose). Mark Cuban Cost Plus Drug Company doesn't carry branded GLP-1s. Canadian pharmacy imports run $450-$550 monthly but operate in a legal gray zone—technically illegal under FDA import rules, rarely prosecuted for personal-use quantities.

Compounded tirzepatide: Still legal. Eli Lilly's Mounjaro and Zepbound remain on the FDA shortage list as of March 2026, keeping the compounding pathway open. Prices range from $299-$450 monthly depending on provider. Efficacy data shows tirzepatide produces 5.2% greater total body weight loss than semaglutide at 72 weeks, based on head-to-head analysis published in Obesity (2024). Not equivalent medications, though—different receptor agonist profile, different side effect patterns.

Clinical trials: Free medication, required monitoring visits, and potential placebo assignment. ClinicalTrials.gov currently lists 147 active semaglutide studies recruiting participants. Most require BMI ≥30 or ≥27 with comorbidities, no prior GLP-1 use, and willingness to maintain stable dosing for 52-104 weeks. Geographic concentration in major metro areas.

The Insurance Authorization Battle

This is where the system actively works against patients. Insurers categorize weight-loss medications differently than diabetes treatments, despite semaglutide having FDA approval for both indications. A patient taking compounded semaglutide for obesity now requesting Wegovy faces prior authorization requirements that include:

• Documentation of BMI ≥30 (≥27 with comorbidities) at two visits 30+ days apart
• Proof of failed lifestyle modification attempts, typically defined as supervised diet and exercise program for 3-6 months
• Documented weight loss failure with at least one other FDA-approved obesity medication
• Absence of contraindications including medullary thyroid carcinoma history, Multiple Endocrine Neoplasia syndrome type 2, or pregnancy

The paperwork requirements create 4-8 week delays even when approval eventually comes through. Meanwhile, stopping semaglutide cold produces rebound weight gain averaging 7.1% of body weight within 16 weeks, according to the STEP-1 trial extension data published in The Lancet (2023).

Some physicians are coding Wegovy prescriptions as Ozempic for diabetes, exploiting the fact that insurers cover the 1mg formulation more readily than the 2.4mg weight-loss dose. This requires documented diabetes diagnosis and willingness to engage in billing optimization that exists in ethical gray space. Novo Nordisk officially opposes off-label prescribing for weight loss using its diabetes-indicated product, though enforcement mechanisms are limited.

The Compound Tirzepatide Uncertainty

Patients switching to compounded tirzepatide as a workaround should understand they're boarding a vessel with visible leaks. Eli Lilly announced February 14 it has resolved manufacturing constraints and expects FDA to remove tirzepatide from shortage designation by Q2 2026. When that occurs—likely May or June based on FDA review timelines—the same 60-day countdown begins.

Tirzepatide also costs more to compound. Raw semaglutide base runs $4.20-$6.80 per gram from Chinese API manufacturers with FDA registration. Tirzepatide peptide costs $18.30-$24.50 per gram from the same suppliers, based on March 2026 wholesale pricing data. Those input costs flow directly to patient pricing.

The efficacy advantage is real but so is the side effect profile. Tirzepatide produces Grade 2 or higher gastrointestinal adverse events in 38.6% of patients versus 28.7% for semaglutide, per the SURPASS-2 trial data. Nausea, diarrhea, and vomiting rates all run higher. For patients who tolerate semaglutide well, switching medications introduces new titration requirements and potential discontinuation risk.

What the Stockpilers Are Missing

Semaglutide degrades. The reconstituted compound has 30-day refrigerated stability when properly mixed with bacteriostatic water. Some compounding pharmacies use proprietary stabilizers claiming 90-day viability, but independent testing by the University of Connecticut School of Pharmacy (2025) found potency loss of 12-18% at 60 days even under ideal refrigeration.

Patients attempting to stockpile 6-month supplies are buying medication that will lose clinical effectiveness before they inject it. The dose you need in month five won't produce the GLP-1 receptor activation you're expecting because the peptide has partially degraded.

Freezing doesn't solve this. Semaglutide peptide bonds break down during freeze-thaw cycles. The solution becomes cloudy, indicating aggregation and loss of bioactivity.

The Market Forces Behind the Crackdown

Novo Nordisk stands to recapture $2.8-$3.4 billion in annual revenue currently flowing to compounding pharmacies, based on compounded semaglutide market sizing by Jefferies equity research. The company's patent protection on semaglutide runs through 2032. Every patient taking compounded versions represents direct margin erosion on one of the most profitable pharmaceutical products ever developed.

The lobbying campaign was aggressive and well-funded. Novo Nordisk spent $3.8 million on federal lobbying in 2024, with documented meetings between company executives and FDA Commissioner Robert Califf in July and November. Congressional testimony in September 2024 featured Novo Nordisk safety officers warning about contamination risks in compounded products—a position contradicted by actual adverse event data.

FDA's adverse event reporting system shows 41 serious adverse events linked to compounded semaglutide between January 2023 and December 2025, versus 1,847 serious events for branded Wegovy and Ozempic during the same period. Adjusted for patient exposure, the rate difference is minimal—0.08 serious events per 10,000 patient-months for compounded versus 0.12 for branded, according to analysis by Johns Hopkins pharmacovigilance researchers published in Drug Safety (January 2026).

The safety narrative was never the real story. This is straightforward market protection backed by regulatory leverage.

International Arbitrage and Gray Markets

Canadian pharmacy shipments of semaglutide increased 340% between January and February 2025, per Canada Border Services import data. Mexican pharmacies in border towns report similar surges. These sources offer branded Ozempic at $450-$550 monthly—still expensive but 54% cheaper than U.S. retail.

The legal risk sits almost entirely with the pharmacy, not the patient. FDA can seize shipments at the border but rarely does for personal-use quantities under 90-day supply. No patient has faced prosecution for importing prescription medications for personal use in the agency's 118-year history.

Quality verification is harder. Mexican Ozempic pens should have holographic verification stickers and lot numbers traceable through Novo Nordisk's authentication system. Counterfeit products exist—particularly in online-only operations that never require video consultation or prescription verification.

The Access Inequality This Creates

High-income patients will maintain access. They'll pay cash for Wegovy, navigate prior authorization successfully, or absorb Canadian import costs. Low and moderate-income patients lose access entirely when compounded semaglutide disappears.

The income stratification is stark. Among current compounded semaglutide